
Medexus Pharmaceuticals Inc has seen a modest price increase this week amidst the absence of major news.
This week, Medexus Pharmaceuticals Inc (MDP.TO) closed at C$4.95, reflecting a slight increase of 1.02% over the past week. Despite a lack of significant news, the company's stock performance remains noteworthy, particularly in the context of its recent fiscal results and product-level performance.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
Market cap
$155.56M
52W high
$5.50
52W low
$2.51
1W change
+1.02%
Beta
1.73
Analyst Price Targets
Based on analyst covering MDP · as of Sep 17, 2026
Wall Street analysts forecast MDP stock price to rise 46.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+46.5% Upside
Current Price
C$4.95
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
28.5%
Annualized
90-Day Vol
39.1%
Annualized
Trend (90d)
-16.6%
Annualized drift
90d Mean
C$4.66
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$4.85 | C$4.40 – C$5.35 |
| 60 trading days | C$4.76 | C$4.14 – C$5.47 |
| 90 trading days | C$4.66 | C$3.94 – C$5.53 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may want to keep an eye on Medexus Pharmaceuticals as it continues to show resilience in a competitive healthcare market, especially with the strong performance of its GRAFAPEX product.
Medexus Pharmaceuticals Inc Stock Performance Overview
With a year-to-date increase of 60.19%, Medexus Pharmaceuticals is showcasing strong momentum, particularly in its product offerings.
Bull case
Analysts have a positive outlook for Medexus Pharmaceuticals, suggesting potential for growth. The average target price is C$7.25, which indicates a possible upside of 46.5% from its current price.
Bear case
On the flip side, concerns arise from the company's negative profit margin and return on equity, which could affect its long-term financial health and investor sentiment.
Recent Price Action
Medexus Pharmaceuticals Inc (MDP.TO) closed at C$4.95 this week, marking a 1.02% increase over the past week and maintaining a year-to-date gain of 60.19%. The stock has seen a minor decline of 2.56% over the past month, but the overall yearly performance remains strong.
Company News and Catalysts
Advertisement
This week, there were no significant announcements or news releases impacting Medexus Pharmaceuticals. However, the company recently held its annual meeting of shareholders, where directors were elected. Earlier in August, the company reported its fiscal Q1 2027 results, highlighting the strongest quarter of product-level performance for GRAFAPEX (treosulfan) to date. These developments indicate a positive trajectory for the company, even in the absence of immediate news.
Technical Picture
From a technical perspective, Medexus Pharmaceuticals is trading slightly below its 50-day moving average of C$5.07, reflecting a 2.3% gap. The stock is well above its 200-day moving average of C$4.00, indicating a robust long-term trend. The 52-week range for MDP.TO is C$2.51 to C$5.50, with the current price sitting at approximately 82% of this range. The beta of 1.73 suggests that the stock is more volatile than the market, which may appeal to risk-tolerant investors.
Insider Activity
No recent insider activity has been reported for Medexus Pharmaceuticals, suggesting a stable ownership structure at this time.
Price Action Summary
As of the last close, Medexus Pharmaceuticals Inc (MDP.TO) remains at C$4.95, reflecting a daily change of 0.00%. The trading volume for the latest session was 31,388 shares, slightly below the 20-day average of 34,320 shares, indicating a lower trading interest relative to recent periods.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement

Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.


